

Rapid LC-UV-MS Characterization of Peptide Therapeutics and Impurities Using BioResolve™ Peptide Phenyl-Hexyl+ and C₁₈+ RP Columns

Natalia Kozlova, Venkata Siva Suryanarayana Gurram, Hua Yang, Stephen Shiner, Balasubrahmanyam Addepalli

Waters Corporation, United States

Published on September 29, 2026

Abstract

Efficient separation and characterization of peptide therapeutics and their impurities are critical for biopharmaceutical development and quality control. This study demonstrates the performance of BioResolve Peptide Phenyl-Hexyl+ and C₁₈+ RP Columns for rapid LC-UV-MS analysis of insulin, its deamidation impurity, cagrilintide, semaglutide, liraglutide, and tirzepatide using a short 2.1 × 50 mm column format. Both column chemistries achieved baseline resolution of all analytes, including the critical separation of insulin from its deamidated impurity. Coupling with the BioAccord LC-MS System provided clean mass spectra, clear charge-state distributions, and accurate monoisotopic mass assignments with low mass error under MS-compatible conditions. These results demonstrate that BioResolve Peptide Phenyl-Hexyl+ and C₁₈+ RP Columns enable fast, robust, and MS-compatible characterization of peptide therapeutics and related impurities in a single LC-UV-MS workflow.

Benefits

- Rapid impurity resolution: Baseline separation of insulin and its deamidation impurity in less than six minutes using a short 2.1×50 mm column format.
- Selective peptide separation: Resolution driven by differences in peptide hydrophobicity, molecular structure, and fatty-acid conjugation.
- Consistent chromatographic performance: Comparable separation quality and elution profiles across Phenyl-Hexyl+ and C₁₈+ Column chemistries.
- MS-ready methodology: Mobile phase conditions fully compatible with LC-MS analysis, enabling seamless chromatographic and mass spectrometric characterization.
- Confident mass confirmation: Clear charge-state distributions facilitate accurate deconvolution and reliable monoisotopic mass determination using intact mass analysis software.
- Accelerated peptide characterization: Enables rapid assessment of peptide therapeutics and impurities within a single LC-UV-MS workflow.




Figure 1. Three-dimensional structures of bovine insulin (PDB:4E7V), liraglutide (PDB:4APD) and PubChem representations of cagrilintide (171397054), semaglutide (56843331), and tirzepatide (166567236) are illustrated.

Introduction

Biologics are the fastest-growing class of therapeutics which include monoclonal antibodies (mABs), recombinant proteins, hormones, vaccines, and gene therapies. Insulin, a peptide hormone that

regulates blood glucose levels, is a key biologic used to treat diabetes resulting from insulin deficiency. This peptide hormone consists of a 21-residue A-chain and a 30-residue B-chain connected by three conserved disulfide bonds. Human and bovine insulins share nearly identical structures and differ by only three amino acid residues (A8, A10, and B30)¹, while bovine and porcine insulins differ at only two positions (A8 and A10), highlighting their high degree of structural conservation. Because insulin-binding regions are highly conserved across species, both human and animal insulin can effectively regulate blood glucose. However, recombinant human insulin and engineered analogs largely replaced animal-derived insulin due to their closer physiological similarity.² Regardless of origin, insulin products may contain process, formulation, stability, or product-related impurities, making their separation and characterization essential for ensuring product quality, efficacy, and regulatory compliance.³

Chain	Human insulin	Bovine insulin
A-chain	GIVEQCCT S ICSLYQLENYCN	GIVEQCCASVCSLYQLENYCN
B-chain	FVNQHLCGSHLVEALYLVCGERGFF Y TPKT	FVNQHLCGSHLVEALYLVCGERGFF Y TPKA
Elemental composition	C257H383N65O77S6	C254H377N65O75S6
Monoisotopic Mass	~5803.638 Da	~5729.601 Da

Table 1. Comparison of human and bovine insulin sequences. Amino acid differences are shown in bold italics.

Glucagon-like peptide-1 receptor (GLP-1R) agonists as well as amylin analogs are another class of peptide therapeutics (Figure 1) that mimic the incretin hormone GLP-1 to improve glycemic control and support weight management.⁴ Their safety, efficacy, and stability depend on critical quality attributes (CQAs), including sequence integrity, chemical modifications, higher-order structure, aggregation, and impurity levels. Analytical characterization is particularly challenging due to their 30-40 amino acid length, fatty-acid conjugation, susceptibility to oxidation, deamidation, truncation, and aggregation.

Peptide	Elemental composition	Length	Monoisotopic mass (Da)
Insulin (bovine)	C254H377N65O75S6	A21-B30	5729.601
Insulin deamidation N	C254H376N64O76S6	A21-B30	5730.585
Cagrilintide	C194H312N54O59S2	37 aa+C20 fatty acid	4406.252
Semaglutide	C187H291N45O59	31 aa+C18 fatty acid	4111.115
Liraglutide	C172H265N43O51	31 aa+C16 fatty acid	3748.947
Tirzepatide	C225H348N48O68	39 aa+2 amino isobutyric acid+ C20 fatty acid	4810.525

Table 2. Elemental composition and monoisotopic mass information of bovine insulin, deamidation impurity, GLP-1 receptor agonists, and amylin analog.

Liquid chromatography coupled with mass spectrometry (LC-MS) is a powerful technique for the characterization of biologics and their impurities. However, even subtle differences in column chemistry can significantly impact method robustness, reproducibility, and analytical performance. Inadequate impurity profiling may compromise product quality, efficacy, and patient safety while increasing the risk of regulatory challenges and product recalls. Here, the rapid and reliable LC-MS analysis of insulin, its deamidation impurity, GLP-1 receptor agonists, and an amylin analog using BioResolve Peptide Phenyl-Hexyl+ and C₁₈+ RP Columns coupled with the BioAccord LC-MS System and waters_connect™ Intact Mass Application are demonstrated. The optimized workflow delivers high-resolution separations, accurate mass measurements, and confident impurity identification, enabling efficient characterization of peptide therapeutics throughout development and quality control.

Experimental

This application note demonstrates the use of BioResolve Peptide Columns for rapid LC-MS characterization of peptide therapeutics and impurities. A mixture of bovine insulin, its deamidation impurity, GLP-1 receptor agonists (semaglutide, liraglutide, and tirzepatide), and the amylin analogue cagrilintide were analyzed in a single injection. Coupled with the BioAccord LC-MS System and waters_connect Intact Mass Application, the workflow delivers efficient separation, accurate mass

confirmation, and streamlined characterization of peptide biologics.

Preparation of Peptide Standards

(i) Insulin: Bovine insulin (Millipore Sigma – p/n: 16634) was dissolved in 0.01N HCl at 2mg/mL concentration and stored at room temperature (~25 °C) for about 96 hours to generate the impurity. After 96 hours, the aged sample was aliquoted and stored at 2 to 8 °C up to 2 weeks or aliquoted and stored at -20 °C for long term storage (~6 months).

(ii) GLP-1 and amylin analog standards: Cagrilintide (Cayman chemicals - p/n: 41329), semaglutide acetate (AA blocks – p/n: AA02C9ME), liraglutide (AA blocks – p/n: AA003R7S) and tirzepatide (AA blocks – p/n: AA01MVAI) were dissolved in Dulbecco's phosphate buffered saline (DPBS – Cytiva p/n: SH30028.02) buffer at 2 mg/mL and stored at 2-8 °C for up to 1 month or aliquoted and stored at -20 °C for long term storage (~6 months).

(iii) Peptide mixture preparation for LC-MS injections: 4 µL of each of the 2 mg/mL solutions of GLP-1, amylin analog and bovine insulin prepared previously were added to 200 µL of 0.1% of formic acid in water:acetonitrile (98:2) and mixed well. 1-2 µL of the sample was injected, providing a total load of 0.45-0.91 µg per injection respectively.

LC Conditions

Equipment	Waters p/n Requirements
ACQUITY™ Premier UPLC System:	ACQUITY Premier UPLC H-Class PLUS Bio SM FTN-H, p/n: 186015086 or equivalent ACQUITY UPLC Premier Bio Binary Solvent Manager (BSM), p/n: 186015061 or equivalent Column Heater (CH-A), p/n: 186015042 or equivalent TUV Detector
TUVE, analytical flow Cell, 500 nL, Low	p/n: 205015033

dispersion:

TUVe inlet (0.0025"):	p/n: 430001749
Column active pre-heater:	p/n: 430005183
50 µL titanium mixer:	p/n: 700012635
Column support clips:	p/n: 205000478
Sample needle (15 µL, SS or PEEK, 0.010" ID):	p/n: 700012821
Empower™ 3 Chromatography Manager or newer:	Base package, System suitability
Feature release:	FR3 or most current (Empower2) FR1 or most current (Empower3)
ACQUITY UPLC System Driver Software:	Version 1.30 or most current
Column heater thermal gasket:	p/n: 430005183
Columns: BioResolve Peptide Phenyl- Hexyl+ RP Column MaxPeak™ Premier Technology, SPP, 1.6 µm, 230Å (2.1 x 50 mm):	p/n: 186011725
BioResolve Peptide C18+ RP Column MaxPeak Premier Technology, SPP, 1.6 µm, 230Å (2.1 x 50 mm):	p/n: 186011716
Mobile phase A1:	0.1% Formic Acid in 100% 18.2MΩ*cm Water (v/v)

Mobile phase A2:	Neat, degassed LCMS Acetonitrile
Mobile phase B1:	0.1% Formic Acid in 100% Acetonitrile (v/v)
Seal wash:	10% Acetonitrile for 5.0 minutes
Needle wash:	1:1:1:1 Methanol:Acetonitrile:Isopropanol:18.2MΩ*cm Water (v/v/v/v) with 0.1% Formic Acid 10 seconds after the injection, no wash before
Active preheater:	Enabled in ACQUITY-FTN method
Pressure limits:	Low: 0 psi High: 15000 psi
Gradient start:	At injection
Data channels:	System Pressure
Column temperature:	55.0 °C
Autosampler temperature:	5 °C
Syringe draw rate:	30 µL/min
Needle placement:	2.0 mm
Air gaps:	Not checked (none)
Data channels:	System Pressure and TUV
Filter setting:	Normal

Data mode:	Absorbance
Autozero on inject start:	Yes
Autozero on wavelength:	Maintain Baseline
UV wavelength:	214 nm
TUV sampling rate:	20 Hz (points/sec) (Peptides),
Injection volume:	1 μ L, 2 μ L, 5 μ L

Chromatography Gradient for GLP Peptide Mixture Batch Test for PH+ Column Chemistry

Time (min)	Flow Rate (mL/min)	%A1	%B1
Initial	0.2	95.0	5.0
1.0	0.2	95.0	5.0
2.0	0.2	89.5	10.5
4.5	0.2	79.0	21.0
5.5	0.2	72.0	28.0
7.5	0.2	63.2	36.8
10	0.2	35.7	64.3
11	0.2	1.0	99.0
11.5	0.2	1.0	99.0
12	0.2	95.0	5.0
20	0.2	95.0	5.0

Chromatography Gradient for GLP Peptide Mixture

Batch Test for C18+ Column Chemistry

Time (min)	Flow Rate (mL/min)	%A1	%B1
Initial	0.2	95.0	5.0
1.0	0.2	95.0	5.0
2.0	0.2	89.5	10.5
3.0	0.2	79.0	21.0
5.0	0.2	73.0	27.0
7.5	0.2	53.0	47.0
9.5	0.2	33.0	67.0
11.0	0.2	1.0	99.0
11.5	0.2	1.0	99.0
12.0	0.2	95.0	5.0
20.0	0.2	95.0	5.0

MS Conditions

MS system: Waters BioAccord LC-MS System

Mode: MS^E

Mass range: 50-2000 *m/z*

Polarity: Positive

Scan rate: 10 Hz


Cone voltage:	20 V
Desolvation temperature:	350 °C
Capillary voltage:	1.2 kV
MS ^E collision energy ramp:	100-150 V
Lock mass correction:	Standard

Data analysis: The waters_connect Intact Mass Application (v1.9.0.2980), operating within the waters_connect Hub (v4.3.0.1318), was used to enable a high-throughput, automated data-processing workflow that minimized manual intervention. To further improve deconvolution performance and mass accuracy, target molecular assignments were refined using theoretical chemical formula information, as previously described.⁵

Results and Discussion

Rapid impurity profiling requires fast and robust chromatographic methods. As shown in Figure 2, BioResolve Peptide Phenyl-Hexyl+ (PH+) and C₁₈+ Columns provided comparable separations of a complex peptide mixture containing insulin, its deamidation impurity, GLP-1 receptor agonists, and an amylin analogue. All analytes eluted within five to nine minutes, with baseline resolution of insulin and its deamidation impurity ($\Delta RT = 0.10\text{-}0.12$ minutes) achieved using a short 2.1×50 mm column. Compared with methods requiring larger columns or longer capillary electrophoresis analyzes, this approach delivers rapid, high-resolution impurity characterization while reducing analysis time and solvent consumption.

A. BioResolve Peptide Phenyl Hexyl+ Column



B. BioResolve Peptide C18+ Column




Figure 2. Separation of bovine insulin, its deamidation impurity, cagrilintide, and GLP-1 receptor agonists using BioResolve Peptide Phenyl-Hexyl+ (A) and C₁₈+ (B) Columns with LC-UV-MS detection. Peak identities were assigned based on retention times of individual standards and confirmed by mass spectral interpretation.

Retention Behavior and Selectivity of PH+ and C18+ Columns

The GLP-1 receptor agonists and cagrilintide exhibited a consistent elution order on both PH+ and C₁₈+ Columns, indicating similar overall hydrophobic selectivity. However, the additional π - π interactions provided by the PH+ chemistry resulted in subtle selectivity differences. Cagrilintide, semaglutide, and liraglutide were retained slightly longer on the C₁₈+ Column (0.08-0.50 minutes), whereas tirzepatide exhibited approximately 0.4 minutes greater retention on the PH+ Column. These differences highlight distinct ligand-stationary phase interactions between the two chemistries.


Notably, all fatty-acid-conjugated peptides, including the GLP-1 receptor agonists and cagrilintide, were retained longer than bovine insulin despite containing fewer amino acid residues. This finding emphasizes the dominant role of lipid conjugation in governing reversed-phase retention and overall peptide hydrophobicity.

Mass Spectral Characterization of Insulin and Its Deamidation Impurity

Despite the similarity of the raw mass spectra, deconvolution with the waters_connect Intact Mass Application revealed an approximately 1 Da mass increase for the impurity relative to bovine insulin (Figure 3). This mass shift is consistent with deamidation of a C-terminal asparagine residue, a well-established insulin degradation pathway reported in the literature. The impurity was slightly better resolved from the main insulin peak on the C₁₈+ Column than on the Phenyl-Hexyl+ Column. On the Phenyl-Hexyl+ Column, a small native monoisotopic peak remained visible for all major charge states of the impurity in the raw spectra, whereas it was completely absent in the impurity spectra acquired on the C₁₈+ Column. Despite this difference, automated data processing confidently assigned the correct masses in both cases.

The reproducibility of the chromatographic separation and mass assignment across both column chemistries and multiple injections highlights the robustness of the LC-MS workflow for insulin impurity characterization.

A. BioResolve Peptide Phenyl Hexyl+ Column



B. BioResolve Peptide C18+ Column




Figure 3. Mass spectral analysis of bovine insulin and its deamidation impurity separated using BioResolve Peptide Phenyl-Hexyl+ (A) and C₁₈+ (B) Columns. For each analyte, the full charge-state distribution (i), enlarged view of the [M+4H]⁴⁺ ion cluster (ii), and deconvoluted neutral mass spectrum (iii) are shown. Insulin data are displayed in the upper panels, with the corresponding impurity data shown below. Mass deconvolution confirmed the expected mass difference between the two species and enabled confident impurity assignment.

Mass Spectral Characterization of GLP-1 Receptor Agonists and Amylin Analogue

Mass spectral analysis of the GLP-1 receptor agonists and the amylin analogue cagrilintide revealed comparable ionization behavior and spectral quality when separated using either BioResolve Peptide

Phenyl-Hexyl+ or C₁₈+ Columns (Figures 4 and 5). Deconvolution of the charge-state distributions using the waters_connect Intact Mass Application enabled confident assignment of the monoisotopic masses for all analytes with low mass error, confirming accurate molecular identification.

Across replicate injections, measured neutral masses exhibited minimal variability, demonstrating the reproducibility and robustness of mass measurements obtained with both column chemistries (Table 3). In addition, the acquisition of clean mass spectra with minimal background interference facilitated straightforward charge-state assignment and mass deconvolution. These results confirm the suitability of both BioResolve Peptide Column chemistries for LC-MS characterization of peptide therapeutics, providing reliable chromatographic performance while maintaining high-quality mass spectral data for confident molecular confirmation. Information related to reproducible performance of analytes on these columns and impurity analysis of GLP-1 receptor agonist can be found in the previous works.




Figure 4. Mass spectral characterization of cagrilintide and GLP-1 receptor agonists separated using a BioResolve Peptide Phenyl-Hexyl+ Column. Peak assignments were confirmed by chromatographic retention times, observed charge-state distributions, and deconvoluted neutral masses generated using the waters_connect Intact Mass Application. Analytes include cagrilintide (6.72 minutes; i), semaglutide (7.56 minutes; ii), liraglutide (7.94 min; iii), and tirzepatide (8.85 minutes; iv). The resulting spectra enabled accurate mass confirmation and confident identification of each peptide therapeutic.




Figure 5. Mass spectral characterization of cagrilintide and GLP-1 receptor agonists separated using a BioResolve Peptide C₁₈+ Column. Peak assignments were confirmed by retention time, charge-state distribution, and deconvoluted neutral mass analysis. Analytes included cagrilintide (7.22 minutes; i), semaglutide (7.69 minutes; ii), liraglutide (8.20 minutes; iii), and tirzepatide (8.46 minutes; iv), each yielding accurate monoisotopic mass confirmation and confident molecular identification.

Peptide	Expected monoisotopic mass (Da)	Observed mass (Da) and mass error			
		PH+ Column	Mass error (ppm)	C ₁₈ + Column	Mass error (ppm)
Insulin (bovine)	5729.601	5729.685	15±9	5729.633	6±7
Insulin N-deamidation	5730.585	5730.666	14±9	5730.626	7±4
Cagrilintide	4406.252	4406.271	4±12	4406.284	7±3
Semaglutide	4111.115	4111.202	21±4	4111.135	5±7
Liraglutide	3748.947	3748.999	14±12	3748.963	4±4
Tirzepatide	4810.525	4810.559	7±9	4810.514	2±3

Table 3. Mass spectral data analysis of insulin, its impurity, GLP-1 receptor agonists and amylin analog following their separation on BioResolve Peptide Phenyl-Hexyl+ and C₁₈+ Columns.

Conclusion

BioResolve Peptide Phenyl-Hexyl+ and C₁₈+ Columns demonstrated excellent suitability for LC-UV-MS characterization of insulin, GLP-1 receptor agonists, and the amylin analog cagrilintide. When coupled with the BioAccord LC-MS System and the waters_connect Intact Mass Application, both column chemistries enabled robust chromatographic performance, accurate mass measurements, and confident molecular identification through automated mass deconvolution. The high chromatographic resolution achieved on a compact 2.1 × 50 mm column format allowed unambiguous separation and characterization of insulin and its deamidation impurity while maintaining rapid analysis times. Furthermore, the absence of significant UV or mass spectrometric interference confirmed the MS compatibility of both stationary phases. Collectively, these results establish BioResolve Peptide Phenyl-Hexyl+ and C₁₈+ Columns as efficient and reliable platforms for the rapid characterization of peptide therapeutics and their related impurities in LC-UV-MS workflows.

References

1. Smith, G. D.; Pangborn, W. A.; Blessing, R. H. The Structure of T 6 Bovine Insulin. *Acta Crystallographica Section D* 2005, 61 (11), 1476–1482. <https://doi.org/10.1107/S0907444905025771>. <
<https://doi.org/10.1107/S0907444905025771>>
2. Heinemann, L.; Richter, B. Clinical Pharmacology of Human Insulin. *Diabetes Care* 1993, 16 (Supplement_3), 90–100. <https://doi.org/10.2337/diacare.16.3.90>. <
<https://doi.org/10.2337/diacare.16.3.90>>
3. Brange, J.; Langkjsgmaeligr, L.; Havelund, S.; Vølund, A. Chemical Stability of Insulin. 1. Hydrolytic Degradation During Storage of Pharmaceutical Preparations. *Pharm. Res.* 1992, 9 (6), 715–726. <https://doi.org/10.1023/A:1015835017916>. <<https://doi.org/10.2337/diacare.16.3.90>>
4. Abdelrahman, R. M.; *et al.* Harnessing GLP-1 Receptor Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon. *J. Obes.* 2025, 2025 (1), 9919810. <https://doi.org/https://doi.org/10.1155/job/9919810>. <
<https://doi.org/https://doi.org/10.1155/job/9919810>>
5. Fox, J.; Denbigh, L.; Berger, S.; Pittman, N. Accelerating GLP-1 Development with High-Throughput LC-MS Using the BioAccord™ LC MS System and the INTACT Mass Application; 2025. Waters Application Note 720009176 <<https://www.waters.com/nextgen/global/library/application-notes/2025/accelerating-glp-1-development-with-high-throughput-lc-ms-using-the-bioaccord-lc-ms-system-and-the-intact-mass-application.html>> .
6. Fagan, A.; Bateman, L. M.; O’ Shea, J. P.; Crean, A. M. Elucidating the Degradation Pathways of Human Insulin in the Solid State. *J. Anal. Test.* 2024, 8 (3), 288–299. <https://doi.org/10.1007/s41664-024-00302-5> <<https://doi.org/10.1007/s41664-024-00302-5>> .
7. Andrasi, M.; *et al.* Determination of Deamidated Isoforms of Human Insulin Using Capillary Electrophoresis. *J. Chromatogr. A* 2020, 1626, 461344. <https://doi.org/https://doi.org/10.1016/j.chroma.2020.461344> <
<https://doi.org/https://doi.org/10.1016/j.chroma.2020.461344>> .
8. Yang, H.; Shiner, S. Separation of a GLP-1 Receptor Agonist and Structurally Similar Impurities Using BioResolve™ Peptide Phenyl-Hexyl+ and C18+ Columns; Milford, 2026. Waters Application Note 720009465 <<https://www.waters.com/nextgen/global/library/application-notes/2026/separation-of-a-glp-1-receptor-agonist-and-structurally-similar-impurities-using-bioresolve-peptide-phenyl-hexyl->

[and-c18-columns.html>](#) .

9. Koza, S. M.; Shiner, S. J.; Lauber, M. A. Reversed-Phase LC-MS Analysis of Low-Abundance Impurities in a GLP-1a Therapeutic Using a Charged Surface 230Å Superficially Porous Phenyl-Hexyl Column. Milford, 2026. Waters Application Note [720009507](#) <
<https://www.waters.com/nextgen/global/library/application-notes/2026/reversed-phase-lcms-analysis-of-low-abundance-impurities-in-a-glp-1a-therapeutic-using-a-charged-surface-230-superficially-porous-phenyl-hexyl-column.html>> .
10. Domain, E.; Kozlova, N.; Addepalli, B.; Hanna, C.; Shiner, S. Unlocking Robust, Reproducible Separations for Modern Peptide Therapeutics with BioResolve™ Peptide Phenyl Hexyl+ Columns; Milford, 2026. Waters Application Note [720009487](#) <
<https://www.waters.com/nextgen/global/library/application-notes/2026/unlocking-robust-reproducible-separations-for-modern-peptide-therapeutics-with-bioresolve-peptide-phenyl-hexyl-plus-columns.html>> .

Featured Products

[ACQUITY UPLC H-Class PLUS Bio System](#) <

<https://www.waters.com/nextgen/global/products/chromatography/chromatography-systems/acquity-uplc-h-class-plus-system.html>>

[BioAccord LC-MS System](#) <<https://www.waters.com/nextgen/global/products/mass-spectrometry/mass-spectrometry-systems/bioaccord-lc-ms-system.html>>

[waters_connect for Quantitation](#) <https://www.waters.com/nextgen/global/products/informatics-and-software/waters_connect-for-quantitation.html>

[Empower Chromatography Data System \(CDS\)](#) <

<https://www.waters.com/nextgen/global/products/informatics-and-software/chromatography-software/empower-software-solutions/empower-cds.html>>

720009594, September 2026



© 2026 Waters Corporation. All Rights Reserved.

[使用条款](#) [隐私声明](#) [商标](#) [招聘](#) [法律和隐私声明](#) [危险化学品经营许可证](#) [Cookie](#) [Cookie设置](#)
[请勿出售我的个人信息](#)

[沪ICP备06003546号-2](#) [京公网安备 31011502007476号](#) [药品医疗器械互联网信息服务备案](#)
[编号: 沪网药械信备字\[2026\]000045号](#)